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BACKGROUND: Combination of bevacizumab and FOLFIRI has currently become one of the standard therapeutic regimens. However,
published information is still limited. The objective of the present retrospective observational study is to analyse the response and
toxicity of first-line treatment with FOLFIRIþbevacizumab in patients with metastatic colorectal cancer (mCRC).
METHODS: Data were collected from patients from nine Spanish sites diagnosed with mCRC, ECOGp2, whose first treatment for
advanced disease was at least three cycles of FOLFIRIþbevacizumab.
RESULTS: A total of 95 patients were enrolled into the study: 64.2% males, median age of 59 years (53.2–67.1 years), ECOG¼0–1in
96.9% of patients. The main site of primary tumour was the colon (69.7%), and most metastases occurred in the liver (71.6%). Clinical
benefit was detected in 67.4% (57.0–76.6; 95% confidence interval (CI)), with 8.4% of CR and 42.1% of PR. Median TTP was 10.6
months (10.0–11.3; 95% CI), PFS was 10.6 months (9.8–11.3; 95% CI), and OS was 20.7 months (17.1–24.2; 95% CI). Main grade
I–II toxicities included haematological toxicity (35.8%), diarrhea (27.3%), mucositis (25.3%), asthenia (19.0%), haemorrhages (11.6%),
and emesis (10.6%). Toxicities reaching grades III–IV were haematological toxicity (9.5%), diarrhea (8.5%), mucositis (5.3%), hepatic
toxicity (2.1%), asthenia (2.1%), proteinuria (1.1%), emesis (1.1%), pain (1.1%), and colics (1.1%).
CONCLUSION: Results of this study support the beneficial effect of adding bevacizumab to FOLFIRI regimen in terms of efficacy and
show a favourable tolerability profile.
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Colorectal cancer (CRC) is the third most common malignancy,
and the fourth cause of death by cancer worldwide. The World
Health Organization (WHO) estimates an incidence of 945000 new
cases yearly and 492000 deaths (WHO, 2003). Colorectal cancer is
considered the second most important cancer location;
it has a growing trend of 2.6% per year and a higher mortality
in males (Lo ´pez et al, 2004). Surgery is the main curative treatment
in early stages. Moreover, a high proportion of patients develop
metastases, which is considered the leading cause of treatment
failure and death (Fortner, 2007).
For 440 years, standard treatment of patients with metastatic
CRC (mCRC) has been 5-fluorouracil (5-FU); various strategies
have been developed to maximise its cytotoxic effect, including
dose modifications, dosage, and route of administration
(Meta-analysis Group in Cancer, 1998). The concurrent adminis-
tration of the biochemical modulator leucovorin (folinic acid, LV)
has improved the efficacy of 5-FU (Thirion et al, 2004).
Furthermore, the combination of irinotecan with the 5-FUþLV
regimen, in bolus or intravenous infusion (FOLFIRI), has
been shown to improve the rate of response and prolong
the progression-free survival (PFS) and overall survival (OS)
(Douillard et al, 2000; Saltz et al, 2000; Kohne et al, 2005). The
results obtained with this regimen have made it the reference
treatment, replacing 5-FUþLV, and permitted to obtain the
United States Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) approvals for irinotecan in
combination with 5-FUþLV, in bolus and in infusion, as first-line
treatment of mCRC. The combination of 5-FUþLV with
oxaliplatin (FOLFOX), developed by the French group, has an
activity similar to FOLFIRI. Either of these two schemes is
considered the standard treatment in first- and second-line mCRC.
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binding to and inhibiting the action of vascular endothelial growth
factor (VEGF) (Presta et al, 1997). Clinical studies have provided a
wide evidence of its efficacy and safety in combination with
various chemotherapy regimens for the treatment of CRC
(Kabbinavar et al, 2003, 2005; Hurwitz, 2004; Hurwitz et al, 2005;
Hochster, 2006), and it has even been considered the only anti-
angiogenic agent that, combined with chemotherapy, has shown to
prolong survival in patients with mCRC (Diaz-Rubio and Schmoll,
2005). This chemotherapy potentiating effect may be associated
with bevacizumab’s effect of reducing tumoural perfusion, vascular
volume, microvascular density, and interstitial fluid pressure.
These effects permit the normalisation of the tumour pressure and
permeability, thus facilitating the access of chemotherapy agents to
the cancer cells (Willett et al, 2004). Additionally, bevacizumab
(Avastin) has been approved by the FDA and EMA as first-line
treatment of mCRC in combination with intravenous regimens of
5-FUþLV with or without irinotecan. One of the most used
regimens with irinotecan is the combination of bevacizumab with
FOLFIRI. However, even though this combination has become
one of the standard therapeutic regimens, published information
to date is still limited. Therefore, this study intends to expand
the current available knowledge, and its main objective consists
of assessing the rate of response to the administration of
bevacizumab in combination with FOLFIRI as first-line treatment
for mCRC.
MATERIALS AND METHODS
Selection criteria
Male and female patients X18 years of age, with an Eastern
Cooperative Oncology Group (ECOG) status p2, histological
diagnosis of advanced (locally advanced or metastatic, non-
resectable) measurable CRC, according to the Response Evaluation
Criteria in Solid Tumours (RECIST). All patients must have had
received at least three cycles of FOLFIRIþbevacizumab as their
first treatment for advanced disease. For patients who had received
prior radiation therapy, the target lesions were selected among
those not irradiated, unless progression of these lesions into the
irradiated field was documented.
Study design and treatment
The primary objective of this multicentre, retrospective, obser-
vational study is to assess the overall response (OR) rate obtained
in patients with locally advanced or metastatic non-resectable
CRC treated with FOLFIRIþbevacizumab. The secondary objec-
tives of this study were to assess the progression-free interval and
the safety profile of the cancer treatment. In order to identify the
information needed to achieve these objectives, oncologists from
nine sites in Spain reviewed the clinical records of 95 patients
treated with at least three cycles of FOLFIRIþbevacizumab during
the previous year.
Assessment of efficacy
The assessment of the efficacy of the FOLFIRIþbevacizumab
combination was done by the investigators according to the
RECIST criteria. All patients had one CT at baseline, after the third
cycle and, then, every three cycles or progression of the disease.
Additionally, the time to progression (TTP), the PFS, and the
OS were assessed.
Assessment of safety
The safety of the FOLFIRI and bevacizumab combination was
assessed based on data collected from the medical charts about the
number and kind of toxicities experienced by the patients included
in the study. The severity of the toxicities was established
according to the toxicity criteria of the National Cancer Institute
(NCI-CTC).
Statistical and analytical methods
The main variable is the rate of response according to the RECIST
criteria, expressed as absolute frequency (n), relative frequency
(%), and the confidence interval (CI) at 95% of the rates of
complete, partial, and OR. In the survival analyses, the following
parameters were included: OS (time between the first treatment
administration and exitus for any cause), TTP (time between the
first treatment administration until progression or death due to
progression), and PFS (time between initiation of treatment until
progression or death due to any cause). These analyses were done
with the Kaplan–Meier method, with a CI of 95%. The safety
results obtained from the population included in the study are
expressed as absolute and relative frequencies of each kind of
adverse event. The statistical analysis was done with the Statistical
Package of the Social Sciences (SPSS), version 17.0.
This study has been conducted in accordance with the directives
established by the Good Clinical Practices directives and the
Declaration of Helsinki. The study protocol has been approved
by the ethics committees, and all the patients have given their
informed consent to participate in the study.
RESULTS
A total of 114 patients were consecutively treated with FOLFIR-
Iþbevacizumab in the Departments of Oncology of nine sites in
Galicia (Spain) from March 2005 to November 2007, 95 of them
fulfilled the inclusion/exclusion criteria (Figure 1). Table 1 shows
the characteristics of the patients at the baseline visit. The median
age was 59 years (range: 53.2–67.1 years), and 96.9% of patients
had an ECOG status 0–1. The most common location of the
primary tumour was the colon (69.7%), whereas the liver was the
most common metastatic site (71.6%).
Assessment of efficacy
The OR (complete response (CR)þpartial response (PR))
was 50.5% (40.1–60.9; 95% CI) of patients, with CR in 8.4% of
cases (3.7–15.9; 95% CI) (Table 2). Moreover, 67.4% (57.0–76.6;
95% CI) of patients obtained clinical benefit (CRþPRþstable
disease (SD)).
The median OS of patients in the study was 20.7 months
(17.1–24.2; 95% CI), the median TTP was 10.6 months (10.0–11.3;
95% CI), and the median PFS was 10.6 months (9.8–11.3; 95% CI)
(Figure 2).
Assessment of safety
The most frequent toxicities throughout the study were the
following: haematological toxicity (45.3%), diarrhea (35.8%),
mucositis (30.5%), asthenia (21.1%), haemorrhages (13.7%), and
emesis (11.6%). These toxicities were also the ones that appeared
as the most common grade I and grade II events (Table 3).
Toxicities reaching grades III–IV were diarrhea, mucositis,
haematological and liver toxicity, proteinuria, asthenia, emesis,
pain, and colic (Table 3).
A reduction, delay, or suspension of treatment due to toxicity
was needed in three of the patients with neutropenia (17.6%),
in three patients with mucositis (17.6%), in the two patients with
liver toxicity (100%), and in two patients with diarrhea (8.3%).
There have been no deaths associated with the study treatment.
Safety and efficacy of bevacizumabþFOLFIRI
RL o ´pez et al
1537
British Journal of Cancer (2010) 103(10), 1536–1541 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sStudy treatment
The median of the cycles of bevacizumabþFOLFIRI was 11.0
(6.0–14.0). Forty-one patients (43.2%) received between 3 and
9 cycles of bevacizumabþFOLFIRI, 42 patients (44.2%) between
10 and 20 cycles, and 12 patients (12.6%) 420 cycles (12.6%).
Treatment with 5-FU and irinotecan was discontinued in 89
patients (94.7%), and bevacizumab was discontinued in 88 patients
(93.6%). The main causes of treatment discontinuation were
progression of the disease (25.9% for 5-FU and irinotecan and
29.5% for bevacizumab) and end of planned treatment (31.8% for
5-FU, 31.8% for irinotecan, and 29.4% for bevacizumab). However,
the development of adverse events was the cause of treatment
discontinuation in only 7.2% of patients receiving 5-FU and
irinotecan, and 8.4% of those receiving bevacizumab.
Surgical treatment of the liver
Surgery for liver metastases was performed in 12 patients (13.8%),
with a mean time from the study treatment to surgery of 5.5 weeks
(range, 2.0–22.0) and curative intention in 11 patients (91.7%).
The number of resected metastases ranged from 1, in five patients
(41.7%), to 4, in two patients (16.7%), and a total resection was
achieved in eight patients (66.7%). During the post-operative
period, anastomotic leak occurred in two patients (16.7%), wound
infection in one patient (8.3%), and intra-abdominal infection in
two patients (16.7%). No patient was operated a second time, and
there were no post-operative deaths.
DISCUSSION
The management of patients with mCRC has considerably changed
in the last few years, mostly due to the incorporation of new agents
such as the anti-VEGF antibody bevacizumab (Omura, 2008). The
results from this study increase the amount of information
available, and support the beneficial effect of adding bevacizumab
to the FOLFIRI regimen for the treatment of mCRC. Moreover,
the rate of response achieved (50.5%), the median of TTP
(10.6 months), of PFS (10.6 months), and of OS (20.7 months)
are in agreement with the results from clinical trials conducted so
far about the combination of bevacizumab and standard regimens
of irinotecanþ5-FUþLV. It should be noted that the patients
included in this study were not selected according to rigid criteria,
and clinical trials can be extrapolated to the general population
under 70 years. The administration of irinotecan, 5-FU, and LV as
first-line treatment for mCRC in intravenous infusion according to
the FOLFIRI regimen has shown to improve the PFS (7.6 vs 5.9
months; P¼0.004) compared with the administration in bolus
(IFL), although no significant differences were reached in the rate
of response (47.2% vs 43.3%, respectively) or in the OS (23.1 vs 17.6
months) (Fuchs et al, 2007). Additionally, adding bevacizumab
Table 1 Patient characteristics at baseline visit (N¼95)
Patient characteristics Value
Median of age, years (range) 59.0 (53.2–67.1)
Gender, n (%)
Male 61 (64.2)
Female 34 (35.8)
ECOG, n (%)
ECOG 0 49 (51.6)
ECOG 1 43 (45.3)
ECOG 2 3 (3.2)
Location of primary tumour, n (%)
a
Colon 66 (69.7)
Rectum 35 (36.8)
Location of metastases, n (%)
Liver 68 (71.6)
Lymph nodes 20 (21.1)
Peritoneum 17 (17.9)
Lung 16 (16.8)
Other 12 (12.8)
Median number of metastatic sites (range) 1.0 (1.0–2.0)
Prior adjuvant treatment, n (%) 35 (36.8)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
aMultiple response,
percentages may exceed 100%.
Total of patients entered:
Evaluable patients: Non-evaluable patients:
N = 114
N = 95 N = 19
Causes of exclusion:
￿   Unknown date of birth (2 patients)
￿   ECOG PS > 2 (4 patients)
￿   Lack of histological diagnosis of CRC (2 patients)
￿   Lack of measurable CRC (3 patients)
￿   <3 cycles of FOLFIRI+bevacizumab (6 patients)
￿   Lack of measurable CRC and <3 cycles of
    FOLFIRI+bevacizumab (2 patients)
Figure 1 Flowchart of patients entered into the study.
Table 2 Response rates (N¼95)
Response rate n % 95% CI
Complete response 8 8.4 3.7–15.9
Partial response 40 42.1 32.0–52.7
Stable disease 16 16.8 9.9–25.9
Progressive disease 31 32.6 23.4–43.0
Abbreviation: CI¼confidence interval.
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to values similar to those obtained in our study (5.9 vs 8.3 months
for IFL and IFLþbevacizumab, respectively; 7.6 vs 11.2 months
for FOLFIRI and FOLFIRIþbevacizumab) (Fuchs et al, 2007).
Even though there were no significant differences between the
administration of FOLFIRIþbevacizumab and IFLþbevacizumab
in the rate of response (57.9% vs 53.3%, respectively) or the PFS
(11.2 vs 8.3 months, respectively), the OS was enlarged in patients
treated with FOLFIRIþbevacizumab (P¼0.007).
Increases in the rate of response (44.8% vs 34.8% (Hurwitz,
2004); 45% vs 35% (Popov, 2008)), smaller than those described in
our study, and very similar PFS (10.6 vs 6.2 months (Hurwitz,
2004); 11 vs 6.5 months (Popov, 2008)) and OS (20.3 vs 15.6
months (Hurwitz, 2004); 20 vs 15 months (Popov, 2008)) were
obtained in clinical trials that added bevacizumab to IFL regimens,
representing a significant improvement compared with the group
treated with IFL only. Even better results have recently been
reported from a single-arm phase II trial, in which FOLFIRIþ
bevacizumab administration achieved a response rate of
65%, and a median PFS and OS of 12.8 and 31.3 months,
respectively (Kopetz et al, 2010).
These results are similar or even better than those obtained with
the administration of other chemotherapy combinations that are
currently under study such as FOLFOX (oxaliplatinþ5-FUþLV)
(OR: 41% (Hochster, 2006), TTP: 8.7 months (Hochster, 2006), OS:
19.6 months (Cassidy, 2008)), CapeOx (capecitabineþoxaliplatin)
(OR: 27%, TTP: 5.9 months (Hochster, 2006)), CAPIRI (capecita-
bineþirinotecan) (OR: 29.4%, PFS: 11.4 months, OS: 15 months
(Moehler, 2009)), or XELOX (capecitabineþoxaliplatin) (PFS:
8.0 months, OS: 19.8 months (Cassidy, 2008)). Additionally,
the incorporation of bevacizumab to some of these regimens
has shown to significantly improve the efficacy, with an increased
rate of response (FOLFOXþbevacizumab: 52% vs 41%; CapeOxþ
bevacizumab: 46% vs 27%), TTP (FOLFOXþbevacizumab: 9.9 vs 8.7
months; CapeOxþbevacizumab: 10.3 vs 5.9 months (Hochster,
2006)), and PFS (XELOXþbevacizumab: 9.3 vs 7.4 months (Tyagi,
2006)). However, this improvement does not represent a substantial
advantage over the regimens of bevacizumabþirinotecanþ
5-FUþLV. Actually, recent randomised clinical trials carried
out to compare FOLFIRIþbevacizumab with other regimens
containing bevacizumab as first-line treatment for mCRC have
not found significant differences in efficacy. Thus, the comparison
of CAPIRIþbevacizumab and FOLFIRIþbevacizumab did not
find significant differences in response rates (40.7% vs 40.4%),
median PFS (10.1 vs 10.5 months) or median OS (29.9 vs
27.9 months) (Ziras et al, 2010). In the same way, comparison of
XELIRI (irinotecanþcapecitabine)þbevacizumab and FOLFIRIþ
bevacizumab did not find significant variation either in response
rates (OR: 38% vs 40%; CR: 4% vs 3%; PR: 34% vs 37%; SD:
20% vs 28%) or in median PFS (14.6 vs 15.8 months) or OS
(20.0 vs 26.2 months) (Pectasides et al, 2010). Although efficacy
results of another clinical trial comparing FOLFOXIRI
(oxaliplatinþ5-FUþLVþirinotecan)þbevacizumab and FOLFIRIþ
bevacizumab are not available yet, the safety analysis of the first
100 randomised patients suggest that both treatments are safe,
with a lower incidence of most grade III–IV toxicities in patients
treated with FOLFIRIþbevacizumab (Falcone et al, 2010).
Table 3 Grades I–II and grades III–IV toxicities (N¼95)
Toxicity
a Grades I–II, n (%) Grades III–IV, n (%)
Haematological toxicity 34 (35.8) 9 (9.5)
Diarrhea 26 (27.3) 8 (8.5)
Mucositis 24 (25.3) 5 (5.3)
Asthenia 18 (19.0) 2 (2.1)
Emesis 10 (10.6) 1 (1.1)
Haemorrhages
b 11 (11.6) 0 (0.0)
Pain 9 (9.7) 1 (1.1)
Nausea 9 (9.5) 0 (0.0)
Hypertension
c 9 (9.5) 0 (0.0)
Constipation 6 (6.4) 0 (0.0)
Proteinuria 3 (3.2) 1 (1.1)
Hepatic toxicity 1 (1.1) 2 (2.1)
Alopecia 3 (3.2) 0 (0.0)
Headache 2 (2.1) 0 (0.0)
Colic 1 (1.1) 1 (1.1)
Hiccups 2 (2.1) 0 (0.0)
Thrombophlebitis 1 (1.1) 0 (0.0)
Wound healing problems 1 (1.1) 0 (0.0)
Allergic reactions 1 (1.1) 0 (0.0)
Dyspnea 1 (1.1) 0 (0.0)
Edema 1 (1.1) 0 (0.0)
Oesophagitis 1 (1.1) 0 (0.0)
Fever
c 1 (1.1) 0 (0.0)
Neuropathy 1 (1.1) 0 (0.0)
aInfection was also reported in one patient, and lung thromboembolism and
haemorrhoids in two patients, but the grade was not recorded.
bTwo patients had
this adverse event, but the grade was not recorded.
cOne patient had this adverse
event, but the grade was not recorded.
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Figure 2 Kaplan–Meier estimates of survival curves: overall survival
(N¼95) (A) and progression-free survival (N¼94) (B).
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aspect of the treatment of cancer patients. However, there is
currently little information available about adverse effects, clinical
management, and effects on subsequent treatments in clinical
practice outside of the clinical trials (Fortner, 2007). In this
respect, this study provides more information based on the review
of the medical charts of patients that received bevacizu-
mabþFOLFIRI as first-line treatment. The results from our study
have shown that bevacizumabþFOLFIRI combination has a good
safety profile, with mostly haematologic toxicity, diarrhea,
mucositis, asthenia, haemorrhages, and emesis, and, in most
cases in grades I–II and only reaching grades III–IV in between
1.1% and 9.5%. This good tolerability is a key factor in identifying
optimal treatment regimens and points at the bevacizumabþ
FOLFIRI combination as a promising candidate for CRC
treatment. However, the intensity and frequency of the described
adverse events does not coincide with results obtained in other
clinical trials on the administration of bevacizumabþ
irinotecanþ5-FUþLV combinations in bolus or infusion, in
which higher percentages of grades III–IV adverse events were
detected (Hurwitz, 2004; Fuchs et al, 2007; Falcone et al, 2010).
Similar discrepancies have been previously described in other
observational studies and mainly attributed to the lack of
documented information in the medical charts, highlighting the
need to improve the detailed information in the medical records in
order to obtain a more complete source of information that will
permit a greater degree of accuracy (Fortner, 2007).
In summary, the results obtained in this study have reached
values for rate of response, TTP, PFS, and OS that support the
beneficial effect of adding bevacizumab to the FOLFIRI regimen as
first-line treatment for mCRC. The high tolerability shown by the
bevacizumabþFOLFIRI regimen suggests that this combination is
a promising candidate for mCRC treatment. However, the
safety profile described might be also influenced by the variability
in the adverse events recording in the patients’ medical charts.
The authors recognise that although the observational studies
provide valuable information, they are not usually capable of
providing strong evidence. This fact, together with the limitations
derived from the retrospective collection of data from medical
charts and the lack of a control group, entails the need to perform
subsequent studies to confirm the results described in the present
manuscript.
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